Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics Inc (TNYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,120
  • Shares Outstanding, K 166,506
  • Annual Sales, $ 0 K
  • Annual Income, $ -111,130 K
  • EBIT $ -97 M
  • EBITDA $ -89 M
  • 60-Month Beta 3.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.78
  • Most Recent Earnings $-0.12 on 11/10/25
  • Next Earnings Date 03/09/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 270.60% (-63.95%)
  • Historical Volatility 95.85%
  • IV Percentile 55%
  • IV Rank 24.32%
  • IV High 862.56% on 11/20/25
  • IV Low 80.41% on 03/03/25
  • Expected Move (DTE 12) 0.1955 (24.09%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,422
  • Volume Avg (30-Day) 978
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 23,702
  • Open Int (30-Day) 21,630
  • Expected Range 0.6160 to 1.0070

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.10
  • Low Estimate -0.15
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6515 +24.56%
on 01/28/26
0.9381 -13.50%
on 02/03/26
+0.0666 (+8.94%)
since 01/06/26
3-Month
0.6515 +24.56%
on 01/28/26
1.5600 -47.98%
on 11/12/25
-0.5385 (-39.89%)
since 11/06/25
52-Week
0.3600 +125.42%
on 05/13/25
2.3500 -65.47%
on 10/10/25
-0.1885 (-18.85%)
since 02/06/25

Most Recent Stories

More News
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with  Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGEâ„¢-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1â„¢ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAKâ„¢-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results  from the MyPEAK ™ -1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second...

TNYA : 0.8115 (+8.20%)
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.8115 (+8.20%)
Piper Sandler Sticks to Their Buy Rating for Tenaya Therapeutics (TNYA)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tenaya Therapeutics, with a price target of $40.00. The company’s shares closed yesterday at $1.77.Elevate Your...

TNYA : 0.8115 (+8.20%)

Business Summary

Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH...

See More

Key Turning Points

3rd Resistance Point 0.9297
2nd Resistance Point 0.8856
1st Resistance Point 0.8485
Last Price 0.8115
1st Support Level 0.7673
2nd Support Level 0.7232
3rd Support Level 0.6861

See More

52-Week High 2.3500
Fibonacci 61.8% 1.5898
Fibonacci 50% 1.3550
Fibonacci 38.2% 1.1202
Last Price 0.8115
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar